How should a patient with rheumatic heart disease and a supratherapeutic INR presenting with a decreasing hemoglobin be managed?

Management of Supratherapeutic INR with Hemoglobin Drop in Rheumatic Heart Disease

Stop warfarin immediately, administer 5-10 mg IV vitamin K plus prothrombin complex concentrate (PCC), provide supportive care with volume resuscitation and blood transfusion as needed, and urgently investigate the bleeding source 1.

Immediate Assessment and Classification

This clinical scenario represents a major bleed by definition, as it involves clinically overt bleeding with hemoglobin decrease ≥2 g/dL 1. The presence of rheumatic heart disease complicates management because these patients typically require long-term anticoagulation for valve disease or atrial fibrillation, creating tension between bleeding and thrombotic risks.

Critical Initial Steps

Stop all anticoagulation and antiplatelet agents immediately 1. Do not wait for laboratory confirmation or imaging—the combination of supratherapeutic INR and falling hemoglobin mandates urgent action.

Reversal Strategy

Administer both vitamin K and PCC concurrently 1:

• IV vitamin K 5-10 mg - provides sustained INR correction over 12-24 hours
• Prothrombin complex concentrate (PCC) - provides immediate INR reversal within minutes

PCC is strongly preferred over fresh frozen plasma because it achieves faster INR correction with substantially lower infusion volumes, which is particularly important in patients with rheumatic heart disease who may have compromised cardiac function 2.

Supportive Care Priorities

While reversing anticoagulation:

• Provide local therapy/manual compression if bleeding source is accessible
• Volume resuscitation with crystalloids
• Blood transfusion to maintain hemodynamic stability and adequate oxygen-carrying capacity
• Urgent investigation to identify bleeding source (endoscopy, imaging, etc.)

Critical Pitfall: Delayed Bleeding Manifestation

Obtain repeat imaging if symptoms worsen despite initially negative studies 2. A case report demonstrates delayed traumatic subarachnoid hemorrhage appearing 12 hours after initial negative CT in a patient with mechanical mitral valve and INR 9.0, which progressed to INR 10.2 despite withholding warfarin 2. This underscores that:

• Bleeding can evolve over hours even after stopping warfarin
• Serial neurologic assessments are mandatory
• Low threshold for repeat imaging with any clinical change

Restarting Anticoagulation Decision Algorithm

Once bleeding is controlled and patient stabilized, assess the following factors 1:

Delay or Withhold Anticoagulation If:

• Bleeding occurred at a critical site (intracranial, intraspinal, intraocular, pericardial, retroperitoneal, or intramuscular with compartment syndrome)
• High risk of rebleeding or death/disability with rebleeding
• Source of bleeding not yet identified
• Surgical/invasive procedures planned

Consider Restarting If:

• Bleeding source identified and controlled
• No critical site involvement
• Patient hemodynamically stable
• High thromboembolic risk from rheumatic heart disease

Rheumatic Heart Disease-Specific Considerations

The thromboembolic risk in rheumatic heart disease is substantial, particularly with:

• Mitral stenosis
• Atrial fibrillation
• Prior embolic events
• Mechanical valve replacement

When restarting anticoagulation after major bleeding 3, 2:

1. Bridge with unfractionated heparin (shorter half-life, easier to reverse than LMWH)
2. Restart warfarin cautiously once hemorrhage confirmed stable on serial imaging
3. Target lower INR range initially (e.g., 2.0-2.5) before escalating to therapeutic range
4. Monitor INR every 1-2 days during reinitiation phase

Identifying Contributing Factors

Investigate causes of supratherapeutic INR 2, 4:

• Recent antibiotic use (especially fluoroquinolones, metronidazole, trimethoprim-sulfamethoxazole)
• Acute alcohol intoxication
• Decreased vitamin K intake (vomiting, dietary changes)
• New medications affecting warfarin metabolism
• Medication non-adherence or accidental overdose
• Intercurrent illness affecting hepatic function

Address these factors before restarting warfarin to prevent recurrence.

Timing of Anticoagulation Resumption

For rheumatic heart disease patients with mechanical valves or high embolic risk, anticoagulation typically should be resumed within 7-14 days after major bleeding, provided:

• Bleeding source controlled
• No ongoing hemorrhage on repeat imaging
• Hemodynamic stability achieved
• Hemoglobin stabilized

Earlier resumption (3-7 days) may be necessary for mechanical mitral valves given their higher thrombotic risk compared to aortic positions 3.

Monitoring Strategy Post-Event

• Daily INR checks until stable in therapeutic range
• Weekly hemoglobin monitoring for 2-4 weeks
• Address modifiable bleeding risk factors (hypertension control, avoid NSAIDs/antiplatelet agents unless absolutely necessary)
• Patient education on warfarin-drug and warfarin-food interactions